1. Home
  2. PAY vs AKRO Comparison

PAY vs AKRO Comparison

Compare PAY & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PAY
  • AKRO
  • Stock Information
  • Founded
  • PAY 2004
  • AKRO 2017
  • Country
  • PAY United States
  • AKRO United States
  • Employees
  • PAY N/A
  • AKRO N/A
  • Industry
  • PAY Computer Software: Prepackaged Software
  • AKRO Biotechnology: Pharmaceutical Preparations
  • Sector
  • PAY Technology
  • AKRO Health Care
  • Exchange
  • PAY Nasdaq
  • AKRO Nasdaq
  • Market Cap
  • PAY 4.0B
  • AKRO 3.9B
  • IPO Year
  • PAY 2021
  • AKRO 2019
  • Fundamental
  • Price
  • PAY $28.69
  • AKRO $51.69
  • Analyst Decision
  • PAY Hold
  • AKRO Strong Buy
  • Analyst Count
  • PAY 5
  • AKRO 6
  • Target Price
  • PAY $36.40
  • AKRO $82.50
  • AVG Volume (30 Days)
  • PAY 696.9K
  • AKRO 1.6M
  • Earning Date
  • PAY 08-07-2025
  • AKRO 08-08-2025
  • Dividend Yield
  • PAY N/A
  • AKRO N/A
  • EPS Growth
  • PAY 74.18
  • AKRO N/A
  • EPS
  • PAY 0.40
  • AKRO N/A
  • Revenue
  • PAY $962,105,000.00
  • AKRO N/A
  • Revenue This Year
  • PAY $27.22
  • AKRO N/A
  • Revenue Next Year
  • PAY $20.11
  • AKRO N/A
  • P/E Ratio
  • PAY $71.03
  • AKRO N/A
  • Revenue Growth
  • PAY 47.78
  • AKRO N/A
  • 52 Week Low
  • PAY $17.70
  • AKRO $21.34
  • 52 Week High
  • PAY $40.43
  • AKRO $58.40
  • Technical
  • Relative Strength Index (RSI)
  • PAY 26.57
  • AKRO 45.35
  • Support Level
  • PAY $30.90
  • AKRO $50.13
  • Resistance Level
  • PAY $31.67
  • AKRO $53.60
  • Average True Range (ATR)
  • PAY 1.10
  • AKRO 2.03
  • MACD
  • PAY -0.33
  • AKRO -0.83
  • Stochastic Oscillator
  • PAY 0.71
  • AKRO 6.37

About PAY Paymentus Holdings Inc.

Paymentus Holdings Inc provides electronic bill presentment and payment services, enterprise customer communication and self-service revenue management to billers and financial institutions through a Software-as-a-Service, (SaaS), secure, omni-channel technology platform. The platform integrates into a biller's core financial and operating systems to provide flexible and secure access to payment processing of credit cards, debit cards, eChecks and digital wallets across a number of channels including online, mobile, IVR, call center, chatbot and voice-based assistants. The Company generates revenue from payment transaction fees processed through the Company's platform. The fees are generated as a percentage of transaction value or a specified fee per transaction.

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

Share on Social Networks: